From a biological perspective, immunohistochemical markers such as Ki-67 and human epithelial growth factor receptor 2 (HER2) and circulating tumour nucleosomes have been suggested to be predictive of the likelihood of breast tumour response to NAC prior to treatment2, 3, 4, 5. The gene discussed is ERBB2; the disease is neoplasm.